An experimental drug for OCD
The study seeks to explore the benefits of an experimental drug as a potential new treatment of obsessive-compulsive disorder (OCD). The experimental drug changes activity in brain areas believed to be involved in OCD.
This study will involve approximately 8-10 weeks of study participation, including eight weeks of investigational treatment.
Study phase: I
Basic eligibility criteria:
Please contact the study coordinator for additional eligibility information.
Aged 21 to 65 years old,
Must have moderate to severe Obsessive-Compulsive Disorder (OCD),
Must have failed at least one routine care treatment,
Women who are pregnant or breastfeeding are not eligible.
Primary disease category: Mental Health
Secondary disease categories: Mental Health
This study is enrolling healthy volunteers.
Protocol number: 1707613822
Projected enrollment dates: April 2019 to December 2020
Official study title: Experimental Treatment of Obsessive Compulsive Disorder